These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29391350)

  • 21. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.
    Facciotto C; Casado J; Turunen L; Leivonen SK; Tumiati M; Rantanen V; Kauppi L; Lehtonen R; Leppä S; Wennerberg K; Hautaniemi S
    Clin Epigenetics; 2019 Dec; 11(1):192. PubMed ID: 31829282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
    Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
    Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
    Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
    Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
    Front Oncol; 2019; 9():994. PubMed ID: 31632920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
    Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
    Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
    Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
    Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
    Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
    Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
    Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
    Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
    Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
    Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
    Cancer Treat Rev; 2024 Jul; 128():102768. PubMed ID: 38797062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
    Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
    Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
    Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.